The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 20, 2018

Filed:

Dec. 15, 2016
Applicants:

Millennium Pharmaceuticals, Inc., Cambridge, MA (US);

Sunesis Pharmaceuticals, Inc., South San Francisco, CA (US);

Inventors:

Weirong Chen, Waltham, MA (US);

Jennifer Cossrow, San Mateo, CA (US);

Lloyd Franklin, Upton, MA (US);

Bing Guan, Needham, MA (US);

John Howard Jones, Framingham, MA (US);

Gnanasambandam Kumaravel, Westford, MA (US);

Benjamin Lane, Chelsea, MA (US);

Adam Littke, Boston, MA (US);

Alexey Lugovskoy, Woburn, MA (US);

Hairuo Peng, Needham, MA (US);

Noel Powell, Westford, MA (US);

Brian C. Raimundo, San Francisco, CA (US);

Hiroko Tanaka, Foster City, CA (US);

Jeffrey Vessels, Marlborough, MA (US);

Thomas Wynn, Salem, MA (US);

Zhili Xin, Lexington, MA (US);

Assignees:

Millennium Pharmaceuticals, Inc., Cambridge, MA (US);

Sunesis Pharmaceuticals, Inc., South San Francisco, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 239/28 (2006.01); C07D 417/14 (2006.01); A61K 45/06 (2006.01); A61K 31/506 (2006.01); C07D 417/12 (2006.01); A61K 31/5377 (2006.01); C07D 413/14 (2006.01); C07D 473/00 (2006.01); A61K 31/52 (2006.01); C07D 471/04 (2006.01); C07F 9/6558 (2006.01); A61K 31/675 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 403/12 (2006.01);
U.S. Cl.
CPC ...
C07D 417/14 (2013.01); A61K 31/506 (2013.01); A61K 31/52 (2013.01); A61K 31/5377 (2013.01); A61K 31/675 (2013.01); A61K 45/06 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01); C07D 473/00 (2013.01); C07F 9/65583 (2013.01);
Abstract

The present invention provides methods of inhibiting Raf kinase activity in a patient, the method comprising administering to the patient a compound having formula I: or a pharmaceutically acceptable salt thereof, wherein R, R, R, L, L, Cy, and Cyare as defined as set forth in the specification.


Find Patent Forward Citations

Loading…